An erectile dysfunction drug that reduces by half the time patients need to take the pill has been approved by the U.S. Food and Drug Administration.» Read More
Biotech earnings kick off Tuesday after the bell as Gilead and Amgen report. Here's what to watch for.
Sarepta Therapeutics got the go-ahead to file for approval of its experimental drug for Duchenne muscular dystrophy.
CNBC's Meg Tirrell reports on a new scientific discovery for the more than $1.7 billion U.S. business of in vitro fertilization. Robert Frank provides insight.
For the first time in several years, Europe's IPO market looks hotter than America's. It could last for some time.
This week the headline appeared to have some tough news for RNA companies, but Alnylam remains undeterred about the potential of its treatments.
Johnson & Johnson turned in a solid first quarter Tuesday, topping analysts' profit and revenue estimates and increasing its 2014 earnings forecast by 5 cents a share.
Shares of Biogen Idec, Celgene, Gilead Sciences, and Lexicon Pharmaceuticals recovered from last week's selloff.
David Joy, Ameriprise Financial, weighs in on Thursday's drastic drop in the Nasdaq, and provides perspective on the outlook for the U.S. economy. We are in a bit of a limbo period now because we are still not getting clean data from the first quarter, Joy says.
Some of the most prominent names in biotechnology plunged on Thursday as the Nasdaq headed for its worst day in nearly two years.
CNBC's Jim Cramer speaks with Robert Hugin, Celgene chairman & CEO, about America's need to build a stronger and more sustainable ecosystem of innovation to continue as the world leader in biomedical innovation.
Eli Lilly and Takeda Pharmaceutical were ordered to pay billions in damages over claims that they concealed cancer risks of its Actos diabetes drug.
Heather Bresch Mylan CEO, discusses the concern over capping drug prices and the impact of Obamacare on rising drug costs.
U.S. health advisers recommended approval of MannKind's inhaled diabetes drug, and said the treatment could help those wary of needles.
Biotech has been so hot the past two years that the sector is starting to raise red flags.
Why do some drugs, like Gilead's Sovaldi, cost more in the U.S. than in other countries. Shelia Dharmarajian reports for "Nightly Business Report."
The FTC has sued pharmaceutical companies $1 billion for delaying the sale of cheaper medicines after patents on brand-name drugs may have expired.
Max Herrmann, partner and healthcare research analyst at Oriel Securities, said biotech stocks have gone through a correction after a "phenomenal" rally.
The U.S. government is prohibited by law from negotiating drug prices, reports CNBC's Sheila Dharmarajan.
A high-priced drug sold by Gilead Sciences is under lawmakers' scrutiny. But one analyst says there's a bigger problem.
Biogen CEO George Scangos talks about future growth opportunities at the company on CNBC's "Fast Money."
Get the best of CNBC in your inbox